Floatz logo

Cediranib

Adult Primary Melanocytic Lesion of Meninges

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Adult Primary Melanocytic Lesion of Meninges cohort.

Asset / SponsorPhaseRating
rg4733
National Cancer Institute (NCI)
Phase 1C
Gadobutrol
University of Southern California
N/AD
GADOBENATE DIMEGLUMINE
University of Southern California
N/AD

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →